Understanding Pituitary Growth After Adrenal Surgery (Nelson Syndrome)
At a Glance
Nelson syndrome is pituitary tumor growth that can occur after both adrenal glands are removed for Cushing disease. Loss of cortisol feedback may drive growth, so regular MRI scans, ACTH hormone tests, and clinical visits are important even without symptoms.
Bilateral adrenalectomy is often a life-changing surgery that successfully resolves the high cortisol levels of Cushing disease [1]. However, for many patients, removing the adrenal glands is not the end of the journey. First, it causes lifelong adrenal insufficiency requiring prescribed glucocorticoid replacement. Second, once the adrenal glands are gone, the body no longer produces cortisol, which previously acted as a “brake” on the pituitary gland. Without this brake, the pituitary tumor that originally caused the Cushing disease can begin to grow again [2].
This growth was historically called Nelson syndrome. Today, medical specialists often use a more descriptive name: Corticotroph Tumor Progression after Bilateral Adrenalectomy (CTP-BADX) [1][3]. It is important to understand that this progression is not a failure of your surgery or a sign that the operation was inadequate; it is a recognized but variable risk that your care team will monitor for years to come [4].
Why the Tumor May Grow
The pituitary gland and the adrenal glands normally work in a “feedback loop.” The pituitary sends out a hormone called ACTH (adrenocorticotropic hormone), which tells the adrenal glands to make cortisol. In a healthy loop, once cortisol levels rise, they signal the pituitary to slow down.
In Cushing disease, a pituitary tumor ignores these signals and pumps out too much ACTH. When both adrenal glands are removed (bilateral adrenalectomy), the source of cortisol is gone. This “loss of negative feedback” means there is nothing left to restrain the tumor cells [2]. While this loss of cortisol is the primary trigger, research shows that some tumors are also naturally more aggressive due to their own genetic makeup, which may explain why some grow faster than others [5][6].
How Common Is Progression?
Because modern imaging is so much more sensitive than the tools used decades ago, doctors now identify tumor progression much more frequently. It is estimated that roughly 30% to 50% of patients will show signs of tumor growth within 10 years after their adrenal surgery [6][4].
- Registry Data: In the European Registry on Cushing’s Syndrome (ERCUSYN), approximately 45% of patients followed after adrenalectomy developed progression [4].
- Timeframes: While it can happen as early as two months after surgery, the risk continues over time. In some studies, the risk of radiographic progression was 27% at three years, rising to 54% at ten years [7][4].
- Radiographic vs. Clinical: Many patients have “radiographic progression”—meaning the tumor grows slightly on an MRI—without ever feeling any symptoms. In one study cohort, over half of the patients showed growth on an MRI, but only about 30% of those eventually required further treatment like surgery or radiation [8].
Shifting Definitions: From Nelson’s to CTP-BADX
The way doctors talk about this condition has changed significantly as technology has improved, though the terms are not perfectly interchangeable.
| Feature | Historical “Nelson Syndrome” | Modern “CTP-BADX” |
|---|---|---|
| Primary Indicator | Hyperpigmentation (skin darkening) and extremely high ACTH [3]. | MRI Evidence showing a new or enlarging tumor [1]. |
| Diagnosis | Often diagnosed only after symptoms were severe [9]. | Diagnosed early through routine, scheduled monitoring [1]. |
| Focus | The “triad” of skin changes, high ACTH, and a known tumor [9]. | Early detection of growth to prevent vision loss or other complications [7]. |
Monitoring and Long-Term Care
Because the risk of progression is an expected part of life after a bilateral adrenalectomy, international guidelines recommend a monitoring framework to catch changes early [1]. This schedule should be individualized based on your own risks.
- Baseline MRI: Usually performed 3 months after your adrenal surgery [1].
- Early Monitoring: An MRI every 12 months for the first 3 years [1].
- Long-term Surveillance: If the tumor remains stable, MRIs may be spaced out to every 2 to 4 years, but you will still need an annual clinical check-up with your endocrinologist [1].
- ACTH Tracking: Your doctor will likely measure your early-morning ACTH levels regularly. A rapid rise in ACTH can be associated with an active tumor and requires closer attention [10][5].
The goal of this monitoring is to ensure that if growth does occur, it is managed before it can affect your vision or press on other critical structures in the brain [11]. While the idea of continued tumor growth is daunting, being proactive with your follow-up appointments is the most effective way to protect your long-term health.
Common questions in this guide
What does Nelson syndrome mean after adrenal surgery?
How common is pituitary tumor growth after bilateral adrenalectomy?
How often should I have MRI scans and ACTH tests after adrenalectomy?
Does a rising ACTH level prove that Nelson syndrome is progressing?
What symptoms of pituitary tumor growth should I report?
Can Nelson syndrome be treated if the tumor grows?
Why do I need glucocorticoid replacement after bilateral adrenalectomy?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Why the tumor grows
Could you explain why the tumor may grow after my adrenal glands are removed?
Monitoring schedule
How often will I need an MRI to check whether the tumor has grown?
Tracking hormone levels
How will my ACTH levels be tracked, and which changes would be important to report?
Get notified when new evidence is published on Nelson syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.
Reincke M, Albani A, Assie G, et al.
European journal of endocrinology 2021; (184(3)):P1-P16.
PMID: 33444221 - 2
The Mechanisms Underlying Autonomous Adrenocorticotropic Hormone Secretion in Cushing's Disease.
Fukuoka H, Shichi H, Yamamoto M, Takahashi Y
International journal of molecular sciences 2020; (21(23)) doi:10.3390/ijms21239132.
PMID: 33266265 - 3
Nelson's syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies.
Patel J, Eloy JA, Liu JK
Neurosurgical focus 2015; (38(2)):E14 doi:10.3171/2014.10.FOCUS14681.
PMID: 25639316 - 4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN.
Valassi E, Castinetti F, Ferriere A, et al.
Endocrine-related cancer 2022; (29(12)):681-691 doi:10.1530/ERC-22-0074.
PMID: 36197784 - 5
Corticotroph tumor progression speed after adrenalectomy.
Bessiène L, Moutel S, Lataud M, et al.
European journal of endocrinology 2022; (187(6)):797-807 doi:10.1530/EJE-22-0536.
PMID: 36206174 - 6
From Nelson's Syndrome to Corticotroph Tumor Progression Speed: An Update.
Bessiène L, Villa C, Bertagna X, et al.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2024; (132(10)):581-590 doi:10.1055/a-2359-8649.
PMID: 38959959 - 7
Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis.
Papakokkinou E, Piasecka M, Carlsen HK, et al.
Pituitary 2021; (24(5)):797-809 doi:10.1007/s11102-021-01158-z.
PMID: 34036460 - 8
Characterizing and predicting the Nelson-Salassa syndrome.
Graffeo CS, Perry A, Carlstrom LP, et al.
Journal of neurosurgery 2017; (127(6)):1277-1287.
PMID: 28084914 - 9
Nelson's Syndrome: An Update.
Fountas A, Karavitaki N
Endocrinology and metabolism clinics of North America 2020; (49(3)):413-432 doi:10.1016/j.ecl.2020.05.004.
PMID: 32741480 - 10
ACTH increment post total bilateral adrenalectomy for Cushing's disease: a consistent biosignature for predicting Nelson's syndrome.
Das L, Bhansali A, Pivonello R, et al.
Pituitary 2020; (23(5)):488-497 doi:10.1007/s11102-020-01047-x.
PMID: 32449103 - 11
Nelson's Syndrome: A Narrative Review.
Torres-Ríos JA, Romero-Luna G, Meraz Soto JM, et al.
Cureus 2023; (15(5)):e39114 doi:10.7759/cureus.39114.
PMID: 37332454
This page explains Nelson syndrome and follow-up after bilateral adrenalectomy for informational purposes only and does not constitute medical advice. Your endocrinology team should interpret your ACTH results, MRI findings, and need for treatment.